Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma.
Pagnuzzi-Boncompagni M, Picco V, Vial V, Planas-Bielsa V, Vandenberghe A, Daubon T, Derieppe MA, Montemagno C, Durivault J, Grépin R, Martial S, Doyen J, Gavard J, Pagès G. Pagnuzzi-Boncompagni M, et al. Among authors: durivault j. Cancers (Basel). 2021 Dec 24;14(1):70. doi: 10.3390/cancers14010070. Cancers (Basel). 2021. PMID: 35008234 Free PMC article.
Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.
Ortholan C, Durivault J, Hannoun-Levi JM, Guyot M, Bourcier C, Ambrosetti D, Safe S, Pagès G. Ortholan C, et al. Among authors: durivault j. Eur J Cancer. 2010 Nov;46(16):3022-36. doi: 10.1016/j.ejca.2010.07.021. Epub 2010 Aug 20. Eur J Cancer. 2010. PMID: 20729074
Disrupting glucose-6-phosphate isomerase fully suppresses the "Warburg effect" and activates OXPHOS with minimal impact on tumor growth except in hypoxia.
de Padua MC, Delodi G, Vučetić M, Durivault J, Vial V, Bayer P, Noleto GR, Mazure NM, Ždralević M, Pouysségur J. de Padua MC, et al. Among authors: durivault j. Oncotarget. 2017 Sep 18;8(50):87623-87637. doi: 10.18632/oncotarget.21007. eCollection 2017 Oct 20. Oncotarget. 2017. PMID: 29152106 Free PMC article.
VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness.
Ndiaye PD, Dufies M, Giuliano S, Douguet L, Grépin R, Durivault J, Lenormand P, Glisse N, Mintcheva J, Vouret-Craviari V, Mograbi B, Wurmser M, Ambrosetti D, Rioux-Leclercq N, Maire P, Pagès G. Ndiaye PD, et al. Among authors: durivault j. Theranostics. 2019 Jan 21;9(3):661-675. doi: 10.7150/thno.27794. eCollection 2019. Theranostics. 2019. PMID: 30809300 Free PMC article.
The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor.
Grépin R, Guyot M, Dumond A, Durivault J, Ambrosetti D, Roussel JF, Dupré F, Quintens H, Pagès G. Grépin R, et al. Among authors: durivault j. Theranostics. 2020 Jan 1;10(3):1107-1121. doi: 10.7150/thno.38346. eCollection 2020. Theranostics. 2020. PMID: 31938054 Free PMC article.
VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells.
Penco-Campillo M, Comoglio Y, Feliz Morel ÁJ, Hanna R, Durivault J, Leloire M, Mejias B, Pagnuzzi M, Morot A, Burel-Vandenbos F, Selby M, Williamson D, Clifford SC, Claren A, Doyen J, Picco V, Martial S, Pagès G. Penco-Campillo M, et al. Among authors: durivault j. Commun Biol. 2020 Oct 16;3(1):579. doi: 10.1038/s42003-020-01306-4. Commun Biol. 2020. PMID: 33067561 Free PMC article.
35 results